Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present new pharmacology data on brilaroxazine as part of two poster presentations at the ASPET 2024 Annual Meeting, to be held in Arlington, VA May 16-19, 2024.
Details for the poster presentation can be found below:
Title: Brilaroxazine Displays Limited Interaction with Clinically Relevant Drug Transporters
Poster Board: 806
Abstract Number: 129049
Room: Independence AB (Independence Level)
Date: Sunday, May 19, 2024
Time: 5:15 – 7:15pm ET
Presenter: Laxminarayan Bhat, Reviva Pharmaceuticals
Location: Hyatt Regency Crystal City, Arlington, VA
Title: Absorption, Metabolism, and Excretion of Brilaroxazine in Rats
Poster Board: 807
Abstract Number: 129061
Room: Independence AB (Independence Level)
Date: Sunday, May 19, 2024
Time: 5:15 – 7:15pm ET
Presenter: Laxminarayan Bhat, Reviva Pharmaceuticals
Location: Hyatt Regency Crystal City, Arlington, VA
Lesen Sie auch
About Brilaroxazine
Brilaroxazine is an in-house discovered new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms.
Positive topline data from the global Phase 3 RECOVER trial in schizophrenia demonstrated the trial successfully met all primary and secondary endpoints with statistically significant and
clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo with a generally well-tolerated side effect profile comparable to placebo and
discontinuation rates lower than placebo. Positive data from a clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects
supports no clinically significant interaction when combined with a CYP3A4 inhibitor. Reviva believes that a full battery of regulatory compliant toxicology and safety pharmacology studies has been
completed for brilaroxazine. Reviva intends to develop brilaroxazine for other neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD) and
attention-deficit/hyperactivity disorder (ADHD).